|
|
|
|
||
Re: How AbbVie Could Hammer Gilead's Hepatitis C FranchiseAlso a Barron's piece on Porges views. Interestingly enough I believe his view is that HCV will only comprise 12% of GILD revenue 5 years from now at $2.9 bil. That thesis suggests $24.16 bil in revenue in 5 years. Which is roughly flat revenue projected over 5 years from 2017 estimates. |
return to message board, top of board |